EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Optimal Duration of Adjuvant Platinum–Etoposide in High-Risk Merkel Cell Carcinoma

Ronen Brenner, Hanna T Frumin Edri, Keren Rouvinov iD, Noa Shani Shrem iD, Amichay Meirovitz, Sabri El-Saied, Ilia Berezhnov, Anna Ievko, Sofiia Turaieva, Shlomit Fenig, Nashat Abu Yasin, Eyal Fenig und 3 weitere

Medicina · 04.05.2026 · 62 (5) · 882

DOI: 10.3390/medicina62050882 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Medicina, online erschienen am 04.05.2026. Verfasst von Ronen Brenner und 14 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute, Edith Wolfson Medical Center, Holon 58220, Israel. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Etoposide, Skin Neoplasms, Platinum. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin malignancy associated with high rates of recurrence and disease-specific mortality. Although adjuvant platinum–etoposide chemotherapy is used in high-risk disease, the optimal number of treatment cycles has not been established. Materials and Methods: This multicenter retrospective cohort study included 104 patients with resected high-risk MCC (pathological stage IIB–III) treated at Israeli medical centers between September 1985 and February 2021. Patients were assigned to one of three treatment groups: radiotherapy alone, four cycles of platinum–etoposide plus radiotherapy, or six cycles of platinum–etoposide plus radiotherapy. The chemotherapy regimen consisted of cisplatin or carboplatin combined with etoposide in 21-day cycles, with the first two cycles administered concurrently with radiotherapy. Primary endpoints were disease-free survival (DFS) and overall survival (OS), analyzed using the Kaplan–Meier method and multivariable Cox proportional hazards regression.

Results

Four cycles of adjuvant platinum–etoposide combined with radiotherapy were associated with the most favorable survival outcomes at all follow-up time points. Five-year DFS and OS in the four-cycle group were 65% (95% CI: 58–72%) and 75% (95% CI: 68–82%), respectively, compared with 55% and 60% in the six-cycle group, and 40% and 45% in the radiotherapy-only group (p < 0.001). The survival advantage of four cycles over radiotherapy alone was sustained at 10- and 20-year follow-up (p < 0.0001). In patients with stage III disease and nodal involvement, the four-cycle group achieved a median DFS of 93 months and a median OS of approximately 110 months, significantly exceeding outcomes in both the six-cycle and radiotherapy-alone groups. No statistically significant survival benefit from chemotherapy was identified in the small subgroup of patients with stage IIB/T4N0 disease.

Conclusions

In patients with high-risk resected MCC, the addition of adjuvant platinum–etoposide chemotherapy to radiotherapy significantly improves DFS and OS, with the greatest benefit observed in patients with stage III disease and lymph node involvement. Four cycles represent an optimal treatment duration, delivering durable long-term survival benefit without the need for more prolonged chemotherapy exposure. These findings support a risk-adapted multimodality approach and provide real-world evidence to guide adjuvant therapy decisions in this rare and aggressive malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellEtoposideSkin NeoplasmsPlatinumHumansRetrospective StudiesFemaleMaleAgedChemotherapy, AdjuvantCisplatinMiddle AgedCarboplatinAged, 80 and overIsraelDisease-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsCohort Studies

Stichwörter der Autor:innen

Merkel cell carcinomaadjuvant chemotherapydisease-free survivalneuroendocrine carcinomaoverall survivalplatinum–etoposideradiotherapy

Substanzen

EtoposideCisplatinCarboplatinPlatinum

Autor:innen und Institutionen

  • Oncology Institute, Edith Wolfson Medical Center, Holon 58220, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
  • The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.
  • Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
  • Institute of Oncology, Kaplan Medical Center, Faculty of Medicine, Hebrew University, Jerusalem 91905, Israel.
  • Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva 49414, Israel.

ORCID-Profile: Keren Rouvinov, Noa Shani Shrem, Walid Shalata

Zitieren

APA

Brenner, R., Edri, H. T. F., Rouvinov, K., Shani Shrem, N., Meirovitz, A., El-Saied, S., Berezhnov, I., Ievko, A., Turaieva, S., Fenig, S., Abu Yasin, N., Fenig, E., Hussany, S., Yakobson, A., & Shalata, W. (2026). Optimal Duration of Adjuvant Platinum–Etoposide in High-Risk Merkel Cell Carcinoma. Medicina, 62(5), 882. https://doi.org/10.3390/medicina62050882

Vancouver

Brenner R, Edri HTF, Rouvinov K, Shani Shrem N, Meirovitz A, El-Saied S, et al. Optimal Duration of Adjuvant Platinum–Etoposide in High-Risk Merkel Cell Carcinoma. Medicina. 2026;62(5):882. doi:10.3390/medicina62050882

BibTeX
@article{Brenner2026,
  author = {Brenner, Ronen and Edri, Hanna T Frumin and Rouvinov, Keren and Shani Shrem, Noa and Meirovitz, Amichay and El-Saied, Sabri and Berezhnov, Ilia and Ievko, Anna and Turaieva, Sofiia and Fenig, Shlomit and Abu Yasin, Nashat and Fenig, Eyal and Hussany, Samer and Yakobson, Alexander and Shalata, Walid},
  title = {Optimal Duration of Adjuvant Platinum–Etoposide in High-Risk Merkel Cell Carcinoma},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {5},
  pages = {882},
  doi = {10.3390/medicina62050882}
}
Kostenlos starten →